Macdonald J S, Kisner D F, Smythe T, Woolley P V, Smith L, Schein P S
Cancer Treat Rep. 1976 Nov;60(11):1597-600.
We report a phase II trial of 5-fluorouracil (5-FU), methyl-CCNU, and vincristine (FMV) combination chemotherapy in advanced colorectal carcinoma. Ten of 25 patients (40%) achieved an objective tumor regression after treatment with FMV chemotherapy. The main toxicities of FMV were hematologic and gastrointestinal. 5-FU was administered in a weekly rather than a loading-dose schedule which allowed for sensitive adjustment of drug dosages according to hematologic toxicity; only 16% of the patients (four of 25) had a wbc count less than 2000 cells/mm3. FMV is significantly more active than 5-FU alone in the treatment of advanced colorectal cancer; however this regimen does not significantly improve survival in responding patients.
我们报告了一项针对晚期结直肠癌的5-氟尿嘧啶（5-FU）、甲基环己亚硝脲（methyl-CCNU）和长春新碱（FMV）联合化疗的II期试验。25例患者中有10例（40%）在接受FMV化疗后实现了客观肿瘤消退。FMV的主要毒性为血液学毒性和胃肠道毒性。5-FU采用每周给药方案而非负荷剂量方案，这样可以根据血液学毒性灵敏地调整药物剂量；只有16%的患者（25例中的4例）白细胞计数低于2000个/mm³。在晚期结直肠癌的治疗中，FMV比单独使用5-FU的活性显著更高；然而，该方案并未显著改善缓解患者的生存率。
